Could cutting immune drugs save kidney transplants during severe infections?
NCT ID NCT06881927
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether reducing immunosuppressive drugs (along with giving a steroid) helps kidney transplant patients recover from septic shock or severe breathing failure in the ICU. About 212 adults whose transplant was at least 3 months ago will be randomly assigned to either lower their usual immune drugs or continue them. The goal is to see if this approach improves organ function without raising the risk of rejection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpitaux Universitaires de Strasbourg
RECRUITINGStrasbourg, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hydrocortisone hemisuccinate (a steroid) and reduction of usual immunosuppressive drugs
What this could lead to
If it works, this could lead to a safer way to manage immunosuppression during critical illness, improving recovery and reducing organ damage in kidney transplant patients.
What could go wrong
This is a Phase 4 trial with 212 participants, so results are not yet proven. Reducing immunosuppression may increase the risk of graft rejection, and the steroid itself has side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.